Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover trial of UX007 in Glut1 DS movement disorders
2015-005536-17Phase 3Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Frequency of disabling paroxysmal movement disorder events. Started Mar 2017; status: terminated.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on 2015-005536-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005536-17.